Literature DB >> 34671576

Pulmonary Involvement Responsive to Enzyme Replacement Therapy in an Elderly Patient with Gaucher Disease.

Dylan Vellas1, Baptiste Gramont1, Rémi Grange2, Pascal Cathébras1.   

Abstract

Type 1 Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder caused by deficient activity of beta-glucocerebrosidase, leading to accumulation of its substrate (glucosylceramide) in macrophages of the reticuloendothelial system, which are then referred to as Gaucher cells. The most frequent symptoms are asthenia, spleen and liver enlargement, bone abnormalities and cytopenia due to bone marrow infiltration. Lung involvement in GD is a rare finding, and it is unclear whether it may regress under enzyme replacement therapy (ERT) or substrate reduction therapy (SRT). Here we report a case of type 1 GD recently diagnosed in an elderly patient complicated by infiltrative lung disease, which responded to ERT. LEARNING POINTS: Type 1 Gaucher disease (GD) is the most common type of GD diagnosed in adulthood, and is characterized by great clinical heterogeneity.Pulmonary involvement is rare, mostly characterized by infiltrative lung disease and pulmonary hypertension, and typically unresponsive to enzyme replacement therapy (ERT).Type 1 GD should be included in the differential diagnosis of infiltrative lung disease of unclear origin in patients with cytopenia and/or splenomegaly.Infiltrative lung disease due to type 1 GD may respond to ERT even in elderly patients. © EFIM 2021.

Entities:  

Keywords:  Gaucher disease; enzyme replacement therapy; infiltrative lung disease

Year:  2021        PMID: 34671576      PMCID: PMC8523375          DOI: 10.12890/2021_002802

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  6 in total

1.  [Gaucher disease: A review].

Authors:  Y Nguyen; J Stirnemann; N Belmatoug
Journal:  Rev Med Interne       Date:  2019-01-11       Impact factor: 0.728

2.  Lung involvement and enzyme replacement therapy in Gaucher's disease.

Authors:  O Goitein; D Elstein; A Abrahamov; I Hadas-Halpern; E Melzer; E Kerem; A Zimran
Journal:  QJM       Date:  2001-08

3.  Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.

Authors:  A Miller; L K Brown; G M Pastores; R J Desnick
Journal:  Clin Genet       Date:  2003-05       Impact factor: 4.438

4.  High-resolution CT pulmonary findings in adults with Gaucher's disease.

Authors:  N A Yassa; A G Wilcox
Journal:  Clin Imaging       Date:  1998 Sep-Oct       Impact factor: 1.605

Review 5.  Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases.

Authors:  Paola Faverio; Anna Stainer; Federica De Giacomi; Serena Gasperini; Serena Motta; Francesco Canonico; Federico Pieruzzi; Anna Monzani; Alberto Pesci; Andrea Biondi
Journal:  Int J Mol Sci       Date:  2019-01-15       Impact factor: 5.923

6.  The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.

Authors:  Jérôme Stirnemann; Marie Vigan; Dalil Hamroun; Djazia Heraoui; Linda Rossi-Semerano; Marc G Berger; Christian Rose; Fabrice Camou; Christine de Roux-Serratrice; Bernard Grosbois; Pierre Kaminsky; Alain Robert; Catherine Caillaud; Roselyne Froissart; Thierry Levade; Agathe Masseau; Cyril Mignot; Frédéric Sedel; Dries Dobbelaere; Marie T Vanier; Vassili Valayanopoulos; Olivier Fain; Bruno Fantin; Thierry Billette de Villemeur; France Mentré; Nadia Belmatoug
Journal:  Orphanet J Rare Dis       Date:  2012-10-09       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.